Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Investor Presentation (June 2019)
14 slides from Anatara Lifesciences's investor presentation, Jun 17, 2019
Slide 1: Anatara Investor Presentation (ASX Release)
ASX Release Anatara Investor Presentation For personal use only BRISBANE & MELBOURNE, 17th June 2019: Anatara Lifesciences (ASX:ANR) releases the presentation which Chief Executive Officer, Mr Steven Lydeamore, will present to investors in Perth this week and to the Gold Coast Investment Showcase la
Slide 2: Bringing Science to Supplements
For personal use only Bringing Science to Supplements June 2019
Slide 3: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 4: Key Investor Message
Key Investor Message For personal use only Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health 3
Slide 5: Key Financial Details
Key Financial Details For personal use only ASX Code Market Share Price1 ANR Capitalisation1 $9.9 million $0.20 Current Cash2 Ordinary Shares Options $6.4 million 49,413,236 2,571,000 • ~$1.25m R&D tax refund received for 2017-18 activities • Sufficiently funded to execute on the development and par
Slide 6: Company Highlights
Company Highlights • First animal product, Detach® - approved for use in piglets in Australia For personal use only • Key appointments with significant human health experience • Sue MacLeman, Dr Jane Ryan, Dr David Brookes, Steve Lydeamore • First human product candidate • Gastrointestinal ReProgram
Slide 7: Animal Health
Animal Health For personal use only • Detach® is a natural, safe, non-antibiotic product that aids in the control of diarrhoea (known as scour) in livestock • In October 2018, the Australian Pesticides and Veterinary Medicines Authority (APVMA) registered Detach® for use in piglets • Commercialisati
Slide 8: From animals to humans
For personal use only From animals to humans 7
Slide 9: Market Opportunity
Market Opportunity Irritable Bowel Syndrome Inflammatory Bowel Disease For personal use only (IBS) (IBD) Affects around 11% of the global population4 >5 million sufferers globally6 ~50% of patients5 turn to dietary supplements 30-50% of IBD patients7 turn to and complementary medicines complementary
Slide 10: Anatara's Unique Dietary Supplement - How does it work?
Anatara’s Unique Dietary Small Intestine Supplement - How does it work? For personal use only Small Intestine Colon Colon Correcting Alleviation of gut microbiota the Repair of gut to restore Reduction of symptomatic lining and normal inflammation diarrhoea barrier defects microbial associated with
Slide 11: Scientifically Proven
Scientifically Proven Successful Proof of Concept Studies For personal use only • Potential breakthrough dietary product • Anatara’s proprietary GaRP formulation was9 efficacious and: • Reduced production of pro-inflammatory proteins by gut and inflammatory cells by >85%; • Reduced the attachment an
Slide 12: Advantages of Dietary Supplements
Advantages of Dietary Supplements* The advantages of a dietary supplement regulatory For personal use only strategy are: Fewer or lower regulatory requirements than pharmaceuticals10 • Lower development cost • Lower development risk • Faster time to market Rapid market penetration11 Public and healt
Slide 13: Clear Path to Commercialisation
Clear Path to Commercialisation 2017 2017 2018 2018 2019 2019 2020 2020 For personal use only H1 H2 H1 H2 H1 H2 H1 H2 Confirmed GRAS status for components with FDA Established collaboration with University of Liverpool (UK) Completed product development plan Patent Application filed Commerci
Slide 14: Anatara Lifesciences Ltd Summary
Anatara Lifesciences Ltd (ASX:ANR) Summary • Innovative, evidence-based products, backed by scientific and clinical For personal use only studies for gastrointestinal health • GaRP dietary supplement seeks to target IBS and IBD patients • Patentable multi-component, dual-targeted formulation • Deliv
Anatara Lifesciences — Investor Presentation (June 2019) on 6ix